Status:

COMPLETED

To Assess the Effect of HDF Versus High Flux Dialysis on Free Light Chains and Cumulative Albumin Loss, in End Stage Renal Disease Patients.

Lead Sponsor:

Ain Shams University

Conditions:

End Stage Renal Disease

Hemodiafiltration

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

Removal of uremic toxins is the main goal of HD, It was improved by using high volume convective technique with high flux (HF) dialyzer. This technique removes medium - large molecular weight solutes ...

Eligibility Criteria

Inclusion

  • Prevalent HD patients on regular hemodialysis sessions for \>6 months 3 sessions/week of 4 hours duration.
  • Patients with Arterio-venous fistula as dialysis access.

Exclusion

  • Patients with hemodialysis catheters.
  • Patients with active inflammation or infection.
  • Decompensated heart failure.
  • Liver Cell Failure ( Child B,C)
  • Patients with known malignancies.

Key Trial Info

Start Date :

February 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2021

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT04747067

Start Date

February 1 2021

End Date

September 1 2021

Last Update

March 16 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ain Shams University Hospitals

Cairo, Governorate, Egypt, 0000

To Assess the Effect of HDF Versus High Flux Dialysis on Free Light Chains and Cumulative Albumin Loss, in End Stage Renal Disease Patients. | DecenTrialz